Inclusion Criteria:

- Adult patients, >/= 18 years of age

- Locally advanced or metastatic non-small cell lung cancer (NSCLC)

- ALK-rearrangement confirmed by FDA approved test

- Phase I: NSCLC that has failed crizotinib treatment

- Phase II: NSCLC that has failed crizotinib and at least one line of platinum-based
chemotherapy treatment

- Measurable disease as defined by RECIST v1.1

- Eastern Cooperative Oncology Group (ECOG) performance status
- Adequate hematologic, hepatic and renal function

Exclusion Criteria:

- Prior therapy with ALK inhibitor other than crizotinib

- Brain metastases that are symptomatic and/or requiring treatment

- History of serious cardiac dysfunction

- History of or current active infection with hepatitis B, hepatitis C or HIV

- Clinically significant gastrointestinal abnormality that would affect absorption of
the drug

- Pregnant or lactating women